- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02628730
Pulmonary Vein Reconnection Following Ablation Index-guided Ablation: a Success Evaluation (PRAISE)
Pulmonary Vein Reconnection Following Ablation Index-guided Ablation: a Success Evaluation (PRAISE)
Atrial fibrillation (AF) is the commonest condition affecting the rhythm of the heart. Tablets to try to normalise the heart rhythm rarely work well. As a result, doctors have devised a treatment called catheter ablation in which special wires are used to deliver heat energy (called ablation lesions) on the inside surface of the heart. Unfortunately, in many patients (almost 1 in 2), some of these ablation lesions recover, and this leads to AF recurrence. Many of these patients then need a second procedure to deliver further ablation at these recovered areas.
Recent research has shown that monitoring of heat delivery with a factor called Ablation Index may be useful in predicting which ablation lesions are less likely to recover. Therefore, we aim to carry out AF ablation guided with Ablation Index (AI) and observe whether this will be associated with better durability of ablation lesions, and thereby better freedom from AF.
This study will include patients with persistent AF, those whose AF episode(s) last for longer than seven days. All patients participating in the study will undergo an initial ablation treatment guided by ablation Index . All patients will undergo a repeat procedure 8-10 weeks after their initial treatment. Any gaps found during the second procedure will be closed again by delivery of ablation.
All participants will be issued with a simple to use handheld heart rhythm monitor, and asked to make a 30-second recording of their heart rhythm each day and also whenever they have symptoms. The monitor stores these recordings and they will be downloaded at review appointments arranged 6 weeks, 3 months, 6 months and 12 months after the initial ablation procedure.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a prospective cohort study in 40 patients with Persistent AF. It will comprise two groups:
- Active Group (AI guided ablation): An initial pulmonary vein isolation (PVI) procedure will be performed guided by AI targets. All patients (regardless of AF recurrence) will undergo a repeat EP study at 8-10 weeks to identify and re-ablate site(s) of PV reconnection
- Historical control group (Contact Force Guided Ablation): will be formed by the 40 patients enrolled to the repeat study arm of the PRESSURE study (ClinicalTrials.gov Identifier: NCT01942408). All 40 patients underwent contact force-guided PVI followed by a repeat EP study after 8-10 weeks.
End-points
Primary outcome measure:
The proportion of patients with pulmonary vein (PV) reconnection seen at repeat EP study
Secondary outcome measures:
- The proportion of reconnected PVs seen at repeat electrophysiology (EP) study
- The proportion of patients maintaining freedom from atrial tachyarrhythmia for 12 months (after an initial 12 week blanking period)
- QOL 6 and 12 months after initial ablation, as quantified by the validated atrial Fibrillation Effect on QualiTy-of-life (AFEQT) and EQ-5D-5Lquestionnaires.
- Rates of major complications occurring within 60 days after a PVI procedure, measured in composite numbers and percentage.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Milan, Italy, 20138
- Centro Cardiologico Monzino, IRCCS,
-
-
-
-
-
Liverpool, United Kingdom, L14 3PE
- Liverpool Heart & Chest Hospital NHS Foundation Trust
-
Newcastle Upon Tyne, United Kingdom, NE7 7DN
- Freeman Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged over 18 years
- Persistent AF (defined, according to the ESC/EHRA Guidelines for the Management of Atrial Fibrillation 2010, as AF episode that either lasts longer than 7 days or requires termination by cardioversion, either with drugs or by direct current cardioversion (DCC) ).
- Symptomatic in spite of drug treatment
- Due to undergo pulmonary vein isolation by RF ablation
Exclusion Criteria:
- Inability or unwillingness to receive oral anticoagulation with a Vitamin K antagonist (VKA) or non-VKA (NOAC) agent
- Previous catheter or surgical ablation procedure for AF
- Unwillingness or inability to complete the required follow-up arrangements
- Current pattern of paroxysmal AF
- Long standing persistent AF (continuous AF longer than 12 months before ablation)
- Prior prosthetic mitral valve replacement or severe structural cardiac abnormality
- Known infiltrative cardiomyopathy
- Known severe left ventricular systolic function (ejection fraction <35%)
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Ablation Index Group
PVI using radiofrequency ablation (RFA) guided by Ablation Index.
|
PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index.
|
OTHER: Reference Group (Contact Force Group)
That group will be formed by the 40 patients who underwent mandatory repeat EPS 8-10 weeks following contact force guided PVI in the PRESSURE study (ClinicalTrials.gov
Identifier: NCT01942408).
RFA ablation data from reference group (Contact Force Group) will be compared with those obtained from the Ablation Index Group.
|
Ablation data from previous ablations, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), that members of this group had in the past, will be compared with those of the Active Comparator Group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The proportion of patients with PV reconnection seen at repeat EP study
Time Frame: 8-10 weeks
|
8-10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of reconnected PVs seen at repeat EP study
Time Frame: 8-10 weeks
|
8-10 weeks
|
|
The proportion of patients maintaining freedom from atrial fibrillation.
Time Frame: 12 months
|
12 months
|
|
Quality of Life (QOL) using score of AFEQT Questionnaire.
Time Frame: 6 and 12 months
|
AFEQT score will be obtained as the sum of units on the questionnaire's scale.
|
6 and 12 months
|
QOL using score of EQ-5D-5L Questionnaire.
Time Frame: 6 and 12 months
|
EQ-5D-5L score will be obtained as the sum of units on the questionnaire's scale.
|
6 and 12 months
|
Major complications percent.
Time Frame: Occurring within 60 days after a PVI procedure.
|
Occurring within 60 days after a PVI procedure.
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Dhiraj Gupta, MD, DM, FRCP, Liverpool Heart and Chest Hospital, Liverpool, UK
- Principal Investigator: Ahmed A Hussein, MRCP, MSc, Liverpool Heart and Chest Hospital, Liverpool, UK
- Principal Investigator: Moloy Das, Freeman Hospital, Newcastle, UK
- Principal Investigator: Antonio D Russo, Centro Cardiologico Monzino
Publications and helpful links
General Publications
- Das M, Wynn GJ, Morgan M, Lodge B, Waktare JE, Todd DM, Hall MC, Snowdon RL, Modi S, Gupta D. Recurrence of atrial tachyarrhythmia during the second month of the blanking period is associated with more extensive pulmonary vein reconnection at repeat electrophysiology study. Circ Arrhythm Electrophysiol. 2015 Aug;8(4):846-52. doi: 10.1161/CIRCEP.115.003095. Epub 2015 Jun 24.
- Hussein A, Das M, Riva S, Morgan M, Ronayne C, Sahni A, Shaw M, Todd D, Hall M, Modi S, Natale A, Dello Russo A, Snowdon R, Gupta D. Use of Ablation Index-Guided Ablation Results in High Rates of Durable Pulmonary Vein Isolation and Freedom From Arrhythmia in Persistent Atrial Fibrillation Patients: The PRAISE Study Results. Circ Arrhythm Electrophysiol. 2018 Sep;11(9):e006576. doi: 10.1161/CIRCEP.118.006576.
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BWI-IIS-386
- NHS REC (REGISTRY: 193216/878714/1/459)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atrial Fibrillation
-
Ablacon, Inc.CompletedArrhythmias, Cardiac | Atrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Longstanding Persistent Atrial FibrillationGermany
-
Ablacon, Inc.RecruitingAtrial Fibrillation | Arrhythmias, Cardiac | Arrhythmia | Atrial Flutter | Atrial Fibrillation, Persistent | Atrial Tachycardia | Atrial Arrhythmia | Atrial Fibrillation Paroxysmal | Atrial Fibrillation, Paroxysmal or PersistentUnited States, Belgium, Netherlands, Czechia
-
Barts & The London NHS TrustAtriCure, Inc.Not yet recruitingAtrial Fibrillation, Persistent | Persistent Atrial Fibrillation | Atrial Arrhythmia | Atrium; FibrillationUnited Kingdom
-
AtriCure, Inc.Active, not recruitingPersistent Atrial Fibrillation | Atrial Fibrillation (AF) | Longstanding Persistent Atrial FibrillationUnited States
-
Maastricht University Medical CenterRWTH Aachen UniversityUnknownAtrial Fibrillation (Paroxysmal) | Atrial Fibrillation Recurrent | Atrial Fibrillation Common Gene VariantsNetherlands
-
Adagio MedicalRecruitingAtrial Fibrillation | Atrial Flutter | Paroxysmal Atrial Fibrillation | Persistent Atrial FibrillationNetherlands, Germany, Belgium
-
Vivek ReddyEnrolling by invitationAtrial Fibrillation and Flutter | Atrial Flutter Typical | Atrial Fibrillation, Paroxysmal or PersistentUnited States
-
Fundació Institut de Recerca de l'Hospital de la...RecruitingAtrial Arrhythmia | Atrial Fibrillation and Flutter | Atrial Fibrillation RecurrentSpain
-
Beijing Anzhen HospitalJohnson & Johnson; Heart Health Research CenterNot yet recruitingParoxysmal Atrial Fibrillation | Persistent Atrial Fibrillation
-
Maastricht UniversityRadboud University Medical Center; Maastricht University Medical CenterRecruitingAtrial Fibrillation | Atrial Fibrillation, Persistent | Atrial Fibrillation ParoxysmalNetherlands
Clinical Trials on PVI using ThermoCool® SmartTouch® Catheter
-
Clinica MediterraneaCompletedAtrial FibrillationItaly
-
Biosense Webster, Inc.CompletedAtrial FibrillationUnited States, Canada
-
Biosense Webster, Inc.CompletedHeart Diseases | Atrial Fibrillation | ArrhythmiaUnited States
-
Keimyung University Dongsan Medical CenterBiosense Webster, Inc.CompletedAtrial FibrillationKorea, Republic of
-
Biosense Webster, Inc.CompletedAtrial FibrillationBelgium, Czechia, Denmark, Italy
-
Johnson & Johnson Medical (Shanghai) Ltd.Completed
-
Barts & The London NHS TrustCompleted
-
Biosense Webster, Inc.CompletedDrug Refractory Symptomatic Paroxysmal Atrial FibrillationUnited States
-
Biosense Webster, Inc.CompletedParoxysmal Atrial FibrillationBelgium, Czechia, Austria, Italy
-
Scott Martin Miller, MDBiosense Webster, Inc.Terminated